Journal of Gastroenterology
First published: 30 November 2017
DOI: https://doi.org/10.1007/s00535-017-1416-0
Yoichi Kakuta, Yoshitaka Kinouchi, Tooru Shimosegawa
Objective: Inflammatory bowel diseases (IBDs), represented by ulcerative colitis and Crohn’s disease, are chronic inflammatory intestinal conditions of unknown etiology.
Methods: The thiopurine drugs 6-mercaptopurine (6-MP) and azathiopurine (AZA) are widely used to treat inflammatory bowel disease. However, the incidence of adverse reactions is high, particularly in Asia, and the mechanisms of toxicity in Asian populations remain unclear. Thiopurine S-methyltransferase (TPMT) is a well-known enzyme that inactivates AZA or 6-MP through methylation and is one of the few pharmacogenetic predictors used in clinical settings in Western countries.
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.